白癜风患者的福音:鲁索替尼乳膏（Ruxolitinib）

Vitiligo is an acquired autoimmune disease characterized by primary, localized or generalized white spots involving the skin and mucous membranes caused by the progressive destruction of melanocytes in the dermis and epidermis. The annual global average incidence of vitiligo is 0.4% to 2%, and it mostly occurs in children and adolescents, with the same gender tendency. Although vitiligo is generally not life-threatening, it can have a serious impact on patients' physical and mental health, study, work and life. Now, the application of (Ruxolitinib) has finally brought good news to patients with vitiligo.

A study conducted a phase II clinical trial of ruxolitinib cream. The results showed that after 24 weeks of topical ruxolitinib, the number of patients with VASI ≥ 50 in the experimental group was significantly greater than that in the control group; at the same time, the adverse reactions of topical ruxolitinib were mild, with only 10% to 15% of patients developing acne. In a 2019 phase III clinical randomized double-blind trial of 1.5% ruxolitinib cream in patients with vitiligo over 12 years old, after 28 weeks of topical treatment (bid), the patients all achieved good results.

Side effects of ruxolitinib cream found in experiments include folliculitis, urticaria, runny nose, nasopharyngitis, ear infection, diarrhea, bronchitis, increased eosinophil count, tonsillitis, etc. Finally, the editor of Medical Companion Travel would like to give a reminder to all patients who are currently using ruxolitinib cream. There are many rumors on the Internet that better effects can be obtained by increasing the dose of the drug. There are also claims that the dose of the drug can be reduced when the side effects are unbearable. These are all wrong. Only by following the doctor's instructions can the drug itself be used to its maximum effect.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.